NASDAQ:VYNE VYNE Therapeutics (VYNE) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free VYNE Stock Alerts $2.47 -0.10 (-3.89%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.41▼$2.8050-Day Range$1.92▼$3.1052-Week Range$1.67▼$8.73Volume76,764 shsAverage Volume121,360 shsMarket Capitalization$34.83 millionP/E RatioN/ADividend YieldN/APrice Target$7.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get VYNE Therapeutics alerts: Email Address VYNE Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside196.2% Upside$7.38 Price TargetShort InterestHealthy0.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.00 out of 5 starsMedical Sector566th out of 907 stocksPharmaceutical Preparations Industry258th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingVYNE Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVYNE Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.80% of the float of VYNE Therapeutics has been sold short.Short Interest Ratio / Days to CoverVYNE Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in VYNE Therapeutics has recently increased by 13.08%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVYNE Therapeutics does not currently pay a dividend.Dividend GrowthVYNE Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VYNE. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for VYNE on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added VYNE Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VYNE Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of VYNE Therapeutics is held by insiders.Percentage Held by Institutions83.78% of the stock of VYNE Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for VYNE Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VYNE Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VYNE Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVYNE Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About VYNE Therapeutics Stock (NASDAQ:VYNE)VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Read More VYNE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VYNE Stock News HeadlinesApril 13, 2024 | finance.yahoo.comVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth PlansMarch 19, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 19, 2024 | globenewswire.comVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 7, 2024 | seekingalpha.comWall Street Breakfast Podcast: NYCB Gets $1B Investment BoostMarch 3, 2024 | finance.yahoo.comVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagFebruary 29, 2024 | markets.businessinsider.comBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical DevelopmentsFebruary 29, 2024 | finanznachrichten.deVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.February 29, 2024 | globenewswire.comVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateFebruary 27, 2024 | finance.yahoo.comVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumFebruary 27, 2024 | globenewswire.comVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumFebruary 21, 2024 | finance.yahoo.comVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 21, 2024 | globenewswire.comVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 2, 2024 | finance.yahoo.comFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired StockJanuary 10, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial ResultsJanuary 3, 2024 | finance.yahoo.comVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of DirectorsNovember 20, 2023 | msn.comVYNE Therapeutics says director Lepore buys 13K shares in coNovember 14, 2023 | finance.yahoo.comCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics IncNovember 13, 2023 | msn.comVYNE Therapeutics files to sell 36.27M shares for holdersNovember 13, 2023 | finanznachrichten.deVYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 13, 2023 | benzinga.comRecap: VYNE Therapeutics Q3 EarningsNovember 13, 2023 | msn.comVYNE Therapeutics GAAP EPS of -$2.01, revenue of $0.1MNovember 13, 2023 | finance.yahoo.comVYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 12, 2023 | markets.businessinsider.comPromising Vitiligo Treatment Trials and Increased Diagnosis Rates Boost VYNE Therapeutics’ Buy Rating: An OverviewNovember 9, 2023 | investing.comVYNE Therapeutics secures $88M PIPE deal to advance clinical programsNovember 7, 2023 | finance.yahoo.comVYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023See More Headlines Receive VYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VYNE CUSIPN/A CIK1566044 Webvynetherapeutics.com Phone(800) 755-7936FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$7.38 High Stock Price Target$9.00 Low Stock Price Target$5.75 Potential Upside/Downside+198.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($7.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,450,000.00 Net Margins-6,710.38% Pretax Margin-6,573.58% Return on Equity-77.46% Return on Assets-62.93% Debt Debt-to-Equity RatioN/A Current Ratio12.73 Quick Ratio12.73 Sales & Book Value Annual Sales$420,000.00 Price / Sales82.92 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book0.39Miscellaneous Outstanding Shares14,100,000Free Float13,845,000Market Cap$34.83 million OptionableNot Optionable Beta1.23 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. David T. Domzalski (Age 57)CEO, President & Director Comp: $1.61MDr. Iain A. Stuart Ph.D. (Age 51)Chief Scientific Officer Comp: $856.82kMs. Mutya Harsch J.D. (Age 49)General Counsel, Chief Legal Officer & Company Secretary Comp: $817.97kMr. Tyler Zeronda (Age 37)CFO & Treasurer Dr. Darrell S. Rigel Faad (Age 73)M.D., Ms, Consultant Comp: $40.2kKey CompetitorsCASI PharmaceuticalsNASDAQ:CASITheratechnologiesNASDAQ:THTXAcurx PharmaceuticalsNASDAQ:ACXPViracta TherapeuticsNASDAQ:VIRXImmunoPrecise AntibodiesNASDAQ:IPAView All CompetitorsInsiders & InstitutionsEventide Asset Management LLCBought 1,394,336 shares on 2/20/2024Ownership: 9.988%Parkman Healthcare Partners LLCBought 696,470 shares on 2/15/2024Ownership: 4.990%Patrick G LeporeBought 13,000 shares on 11/15/2023Total: $50,830.00 ($3.91/share)View All Insider TransactionsView All Institutional Transactions VYNE Stock Analysis - Frequently Asked Questions Should I buy or sell VYNE Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VYNE Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" VYNE shares. View VYNE analyst ratings or view top-rated stocks. What is VYNE Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for VYNE Therapeutics' shares. Their VYNE share price targets range from $5.75 to $9.00. On average, they expect the company's share price to reach $7.38 in the next twelve months. This suggests a possible upside of 196.2% from the stock's current price. View analysts price targets for VYNE or view top-rated stocks among Wall Street analysts. How have VYNE shares performed in 2024? VYNE Therapeutics' stock was trading at $2.33 at the beginning of the year. Since then, VYNE shares have increased by 6.9% and is now trading at $2.49. View the best growth stocks for 2024 here. Are investors shorting VYNE Therapeutics? VYNE Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 85,600 shares, an increase of 590.3% from the March 15th total of 12,400 shares. Based on an average trading volume of 125,900 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.7% of the shares of the company are sold short. View VYNE Therapeutics' Short Interest. When is VYNE Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VYNE earnings forecast. How were VYNE Therapeutics' earnings last quarter? VYNE Therapeutics Inc. (NASDAQ:VYNE) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.30. The business earned $0.08 million during the quarter, compared to the consensus estimate of $0.15 million. VYNE Therapeutics had a negative net margin of 6,710.38% and a negative trailing twelve-month return on equity of 77.46%. When did VYNE Therapeutics' stock split? Shares of VYNE Therapeutics reverse split on Monday, February 13th 2023. The 1-18 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of VYNE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other VYNE Therapeutics investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Organigram (OGI), Zosano Pharma (ZSAN), KushCo (KSHB), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), Sorrento Therapeutics (SRNE) and Aeterna Zentaris (AEZS). How do I buy shares of VYNE Therapeutics? Shares of VYNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VYNE) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
